GlassScriptPhysician profile
John H Roof
NPI 1275067670
$1,700.58
in general payments reported to CMS, 2019-2025
20 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.01 · 2022: $47.44 · 2023: $647 · 2024: $736 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,584 · Education: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,584.13 |
| Education | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $400.80 | 2021-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $349.16 | 2023-2025 | Camzyos, Eliquis |
| Amgen INC. | $173.93 | 2024-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $162.88 | 2024-2025 | General - Therapies |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $130.69 | 2022-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $95.53 | 2023 | Opsumit, Uptravi |
| United Therapeutics Corporation | $86.10 | 2023 | |
| Novartis Pharmaceuticals Corporation | $42.55 | 2024-2025 | |
| Abbott Laboratories | $30.85 | 2021-2023 | Cardiomems |
| Novo Nordisk INC | $28.58 | 2024 | Ozempic, Rybelsus |
| Pfizer INC. | $26.72 | 2025 | |
| Abiomed | $23.81 | 2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.78 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.37 | 2024 | |
| Alnylam Pharmaceuticals INC. | $21.21 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $18.83 | 2024 | |
| Medtronic, INC. | $18.00 | 2024 | |
| Janssen Pharmaceuticals, INC | $16.71 | 2023 | Xarelto |
| Atricure, INC. | $16.50 | 2025 | Synergy Ablation System |
| Merck Sharp & Dohme LLC | $13.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Roof listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.